文献速递临床试验与 GCP医学人工智能与信息学真实世界研究与卫生经济

基于远程编程平台的脊髓电刺激植入慢性顽固性疼痛患者精准管理系统:随机对照试验研究方案(PreMaSy研究)

Precise management system for chronic intractable pain patients implanted with spinal cord stimulation based on a remote programming platform: study protocol for a randomized controlled trial (PreMaSy study).
PubMed 文献 · Trials · 2023-09-11

PreMaSy研究为随机对照试验,拟纳入82例慢性顽固性疼痛患者,在脊髓电刺激电极植入后VAS评分降低超过50%者植入脉冲发生器并1:1随机分为实验组(App自评精准管理系统)与对照组(每月在线随访),主要结局为术后1、3、6个月EQ-5D-5L效用值,旨在检验该系统的非劣效性。

要点

  • 拟纳入82例慢性顽固性疼痛患者,电极植入后VAS降低超过50%者随机分组。
  • 实验组使用智能手机App进行每日疼痛评估与自我参数调整,对照组每月在线随访。
  • 主要结局为术后1、3、6个月EQ-5D-5L效用值,设计为非劣效性检验。

核心结论

  • PreMaSy研究旨在评估基于App的以患者为中心的自我评估管理系统对慢性顽固性疼痛的有效性与安全性。
  • 设计为随机对照试验,检验该精准管理系统相较于每月在线随访的非劣效性。
  • 预期在精准医学方面积累有价值经验。

研究设计与样本

  • 随机对照试验,拟纳入82例慢性顽固性疼痛患者。
  • 电极植入后测试刺激效果,VAS评分降低超过50%者植入脉冲发生器并1:1随机分为实验组或对照组。
  • 所有参与者通过智能手机App完成在线随访和评估。

主要发现

  • 每日疼痛特征评估和每月生活质量问卷整合入App,参与者需完成这些评估。
  • 每日监测疼痛强度VAS,并根据基线VAS设定阈值,达到阈值即安排干预预约。
  • 主要结局为EQ-5D-5L评估的健康状况和生活质量,于基线及术后1、3、6个月评估效用值。

关键数值与推荐

  • VAS评分降低超过50%者方可植入脉冲发生器并随机分组。
  • 主要结局指标为EQ-5D-5L效用值,评估时间点为基线及术后1、3、6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spinal cord stimulation (SCS) is a surgical technique used in patients with chronic intractable pain, and its effectiveness and safety have been validated by multiple studies. However, to maintain an optimal and steady long-term effect is still challenging. Here, we report a new management paradigm integrating smartphone application and remote programming. Chronic pain patients with SCS implants can monitor their pain status on the phone and change stimulation parameters accordingly. The PreMaSy study is a randomized controlled trial to evaluate the clinical effectiveness and safety of this precise management system. METHODS: Patients with chronic intractable pain will be screened for eligibility, and 82 participants are anticipated to be enrolled in this trial. After the electrode implantation, the stimulation effectiveness will be tested. Participants with a reduction of more than 50% in the visual analog scale (VAS) will receive implantation of an implantable pulse generator and randomized (1:1) into the experimental group or control group. All participants will be asked to take online follow-ups and complete assessments using a smartphone application. Daily pain characteristic assessments and monthly quality of life questionnaires are integrated into the App, and participants will be required to complete these assessments. The daily VAS for pain intensity will be monitored and a threshold will be set based on baseline VAS score. The interventional appointment will be scheduled once the threshold is reached. The primary outcome is the health condition and quality of life assessed by the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). Utility values of EQ-5D-5L will be assessed at baseline and 1, 3, and 6 months post-operative. DISCUSSION: The PreMaSy study aims to evaluate the effectiveness and safety of a novel App-based, patient-centered, self-assessment management system for chronic intractable pain. A randomized controlled trial is designed to test the non-inferiority of this precise management system compared to the monthly online follow-ups. It is also expected to yield valuable experiences regarding precision medicine. TRIAL REGISTRATION: ClinicalTrials.gov NCT05761392. Registered on March 07, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Xie D, Han Y, et al. Precise management system for chronic intractable pain patients implanted with spinal cord stimulation based on a remote programming platform: study protocol for a randomized controlled trial (PreMaSy study). Trials. 2023. PMID: 37691092. doi:10.1186/s13063-023-07595-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。